Screener / SEC EDGAR /CIK 0001420800 /10-K filed Feb 26, 2026, compared with Feb 26, 2025 /Numbers from the XBRL of the 10-Ks
Health care peers:
NYSE Health care · Medical Devices

Enovis CORP ENOV

Headquarters
Lewisville, TX
CEO
Damien McDonald
Next results
around Feb 25, 2027
Compare with peers Embed

Where each dollar of revenue went, FY2021

Revenue of $1.4B through the costs to a net profit of $71.7M · income statement of the 10-K

5% net margin
Revenue to Gross profit: $777.7MRevenue to Cost of revenue: $648.5MGross profit to Net profit: $71.7MGross profit to Costs, tax, other: $706.0M Revenue: $1.4B REVENUE $1.4B +27% Y/Y Gross profit: $777.7M · 55% margin GROSS PROFIT $777.7M 55% margin · +29% Y/Y Cost of revenue: $648.5M · 45% of revenue COST OF REVENUE $648.5M 45% of revenue Net profit: $71.7M · 5% margin NET PROFIT $71.7M 5% margin · +68% Y/Y Costs, tax, other: $706.0M · 50% of revenue COSTS, TAX, OTHER $706.0M 50% of revenue
Gross profit $777.7M 55% margin · +29% Y/Y
Net profit $71.7M 5% margin · +68% Y/Y
The full income statement, year by year

ENOV among Health care peers

Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.

Compare
Revenue growth: 6.7%, above 34% of 154 peers (their median 10.5%) REVENUE GROWTH 6.7% · above 34% Gross margin: 61.3%, above 48% of 107 peers (their median 63.8%) GROSS MARGIN 61.3% · above 48% Operating margin: -20.6%, above 17% of 138 peers (their median 10.2%) OPERATING MARGIN -20.6% · above 17% Net margin: -22.9%, above 17% of 153 peers (their median 6.8%) NET MARGIN -22.9% · above 17% FCF margin: 3.0%, above 28% of 144 peers (their median 10.1%) FCF MARGIN 3.0% · above 28%
ENOV Peer median Below the median

What changed

4 new risk paragraphs and 1 accounting fact worth reading about. 10-K filed Feb 26, 2026 against Feb 26, 2025.

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

Accounting checks

11 checks on the latest 10-K. Checks, not verdicts.

How it works

1fact worth reading about the other 10 checks found nothing to note

  • Critical audit matters changed
    New this year: Evaluation of Goodwill Impairment (“At December 31, 2025, the Company’s goodwill allocated to the Prevention & Recovery reporting unit and Reconstructive reporting unit was $401 million and $317 million, respectively. As discussed in Note 2 to the consolidated financial statements, goodwill is not amortized, but rather is subject to a”). No longer listed: Goodwill; Valuation of intangible assets acquired in a business combination
  • Receivables +8.8% ($407.0M to $442.8M) vs revenue +6.7% ($2.1B to $2.2B), +2.1 pts apart
9 more checks with nothing to note
  • Cash from operations $217.3M vs net income −$1.2B (FY ending Dec 31, 2025)
  • Inventory +6.8% ($547.1M to $584.4M) vs revenue +6.7% ($2.1B to $2.2B), +0.1 pts apart
  • Same auditor in both 10-Ks: Ernst & Young LLP
  • No statement of substantial doubt about going concern
  • No 8-K item 4.02 in the last 2 years
  • No NT 10-K or NT 10-Q in the last 2 years
  • No sentence in the 10-K concludes that controls were not effective because of a material weakness
  • No 8-K item 2.06 in the last 2 years
  • No 8-K item 1.03 in the last 2 years

In their words

4 paragraphs in Risk Factors that were not in the 10-K filed Feb 26, 2025. Quoted as filed.

All 4 new paragraphs
  1. Item 1A · new paragraph · not in the 10-K filed Feb 26, 2025 10-K, ITEM 1A
    Our use of artificial intelligence and machine‑learning technologies may expose us to operational, regulatory, and reputational risks. We use, and may increasingly use, artificial intelligence (“AI”) and machine‑learning technologies to support aspects of our operations, product development, and business processes. AI technologies are…
  2. Item 1A · new paragraph · not in the 10-K filed Feb 26, 2025 10-K, ITEM 1A
    In addition, changes in political conditions in China and changes in the state of China-U.S. relations, including any tensions relating to potential military conflict between China and Taiwan, are difficult to predict and could adversely affect our business. Furthermore, if other countries, including the United States, become further…

New risk paragraphs, against peers

Latest 10-K of each, Health care companies closest in revenue

Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.

Financial performance

Last 4 fiscal years · 10-K XBRL

All years
MetricFY2022FY2023FY2024FY2025
Revenue$1.6B$1.7B$2.1B$2.2B
Net income−$13.3M−$33.3M−$825.5M−$1.2B
Operating cash flow−$55.9M$135.0M$113.5M$217.3M
Free cash flow−$161.3M$12.8M−$67.2M$19.9M

Revenue, FY2016 to FY2025

Ten fiscal years, each from its own 10-K · XBRL · USD

$2.2B ▲ 6.7% in FY2025

FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Every number, year by year

Recent filings

5 filings in the last 30 days · SEC EDGAR

All filings

About the company

Enovis CORP, Lewisville, TX · from the 10-K filed Feb 26, 2026

Enovis Corporation (the “Company”, “Enovis”, “we” or “us”) is a medical technology company focused on developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows by manufacturing, and distributing high-quality medical devices with a broad range of products used for reconstructive surgery, rehabilitation, pain management and physical therapy. Our products address the continuum of patient care from injury prevention to rehabilitation after surgery or injury or from degenerative disease, enabling people to regain or maintain their natural motion.

Headquarters
Lewisville, TX
Country
United States
Reports in
USD
Listed on
NYSE
Fiscal year ends
December 31
Last results
Nov 5, 2026
Incorporated in
DE

Email alerts

Sources

The 10-K filed Feb 26, 2026 (open at SEC), compared with the 10-K filed Feb 26, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.

Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ENOV/export.csv") into a cell.

Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.